Abstract
These two applications claim small peptide and benzamide derivatives of acetonitrile, mostly a-substituted, as inhibitors of the Cathepsins. They are shown to be inhibitors of cathepsin L with potencies in the 40 nM range. They are claimed to be useful in treating chronic obstructive pulmonary disease (COPD) and diseases mediated by cathepsin L or cathepsin S.